Insys Therapeutics Inc (NASDAQ:INSY) reported that Andrew G. Long has been engaged as Chief Financial Officer of the company, effective August 7, 2017. Long is a professional finance executive with 3 decades of experience in the bio-pharma, industrial and life sciences sectors. He brings to company a varied set of experiences, which he got at firms famous for grooming top finance talent. His extensive skillset comprises: operational and corporate finance, supply chain, strategy, M&A integration, talent acquisition and development, and information technology.
Insys reported that he recently served as SVP of Global Finance at Patheon, where he worked broadly with their corporate and operational finance team members on numerous measures leading up to Patheon’s IPO. Before that, Long spent nine years offering financial operations and management expertise as VP of Global Finance for numerous segments at Thermo Fisher Scientific. He earlier spent five years heading global financial planning, analysis and reporting activities for the BioScience segment of Cambrex Corporation. Previously, Long also spent around a decade establishing his financial expertise in different roles at Abbott Laboratories.
Saeed Motahari, the President and CEO of Insys, reported that Long is a results-oriented, advanced pioneer with extensive international financial experience. His proven record and breadth of experience of building firms and developing talent will counterpart the strengths of their senior management team. They look forward to his guidance and leadership as they focus on growing their business and advancing their pipeline candidates. Motahari added that he would like to thanks Mr. Darryl Baker, who has worked as company’s CFO since Insys’s IPO in 2013, for his many contributions and commitment to company.
Insys Therapeutics comes in the list of specialty pharmaceutical firm that commercializes and develops innovative drugs and unique drug delivery mechanisms of therapeutic molecules that enhance